System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Yüksel Ürün is an expert in Oncology at Ankara University (Turkey). As of October 2026, ScienceLeadR ranks Yüksel Ürün in the top 1% of experts worldwide for Kidney Neoplasms, Urologic Neoplasms and Urogenital Neoplasms. Yüksel Ürün has authored 296 publications, the most recent in 2026, and is an investigator in 21 clinical trials, 12 of them ongoing. SLR score: 1,594 (community average: 125). How the SLR is computed.

LeadR Profile

Yüksel Ürün Ankara University Turkey
1 594 ScienceLeadR Reputation 1594

Unlock

Register Login
Network Map

Oncology

Subspecialties: Urology - Hematology - Nuclear Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2011 - 2026
Source: PubMed

Ankara University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 296

Citations

Citations: 5 432 1st author: 26 Last author: 114 Unique author: 1

Main journals

J Clin Oncol 29
Ann Oncol 13
Future Oncol 13
J Oncol Pharm Pract 11
Eur J Cancer 10

Best Journals

J Clin Oncol 17
Ann Oncol 9
N Engl J Med 8

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference.
PMID 42934071 — urology, neoplasms, prostate, prostatic neoplasms		Eur Urol20260
Real-World HRR Testing Pathways and Patterns of Detected Alterations in Prostate Cancer From the Multinational ARON-3 Study.
PMID 42862920 — research design, genes, genomics, poly(adp-ribose) polymerases, neoplasms, prostate, poly adenosine diphosphate ribose, biomarkers, recombinational dna repair, prostatic neoplasms, precision medicine		Prostate20260
Global Disparities in the Availability and Reimbursement of Systemic Therapies for Renal Cell Carcinoma: Results of the International ARON-AID Survey.
PMID 42836687 — cells, radiation oncologists, oncologists, pharmaceutical preparations, neoplasms, income, carcinoma, renal cell, therapeutics		Oncologist20260
Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.
PMID 42705254 — research design, progression-free survival, ovary, neutropenia, neoplasms, bevacizumab, drug therapy, maintenance, drug-related side effects and adverse reactions, ovarian neoplasms, response evaluation criteria in solid tumors, therapeutics, carcinoma, ovarian epithelial, chemotherapy		Lancet Oncol Top journal20260
Physicians' Knowledge, Attitudes, and Barriers Toward Clinical Trial Participation in Türkiye: A Cross-Sectional Survey and Implications for Oncology Research Capacity.
PMID 42757281 — cross-sectional studies, biomedical research, physicians, research, therapeutics, education, physician engagement		J Multidiscip Healthc20260

Clinical Studies 21

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4 Study Director: 2

By phase:

Phase 3 16
N/A 3
Phase 1/Phase 2 1
Phase 2 1

By status:

Active not recruiting 8
Recruiting 6
Completed 5
Not yet recruiting 2

By type:

Interventional 18
Observational 3

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 1
multicentric5to9 1
multicentricup10 16

Main Topics

Ongoing Clinical Trials

12 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Terbium 161 PSMA in Lutetium 177 PSMA Naive Patients
NCT07441837 — safety, blood, single photon emission computed tomography computed tomography, neoplasms, prostate, drug-related side effects and adverse reactions, prostatic neoplasms, therapeutics		Phase 2Not yet recruiting2026
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380 — urinary bladder, carcinoma, transitional cell, urinary bladder neoplasms, cells, safety, urinary tract, neoplasms, neoplasm metastasis, carcinoma		Phase 3Recruiting2025
A Study of Tersolisib (LY4064809 STX 478) With Other Anti Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336 — anastrozole, fulvestrant, breast neoplasms, pharmaceutical preparations, neoplasms, letrozole, neoplasm metastasis, breast, therapeutics, mutation		Phase 3Recruiting2025
Prostate Cancer Study of Patient Experiences
NCT07096596 — neoplasms, prostate, prostatic neoplasms, patient reported outcome measures		N/ANot yet recruiting2025
Prostate Cancer Care Disparity Analysis Project (ProGAP)
NCT06612034 — human development, neoplasms, income, prostate, prostatic neoplasms		N/ARecruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS